What question did this study set out to answer?

This research aims to compare the effectiveness of GLP-1 receptor agonists and aspirin in reducing colorectal cancer risk.

January 18, 2026Cancer Discovery0 citations

View Full Paper

GLP-1s Spur Greater Reduction in Colorectal Cancer Risk than Aspirin

Key Points

This research aims to compare the effectiveness of GLP-1 receptor agonists and aspirin in reducing colorectal cancer risk.
Conducted a large retrospective study
Compared incidence of colorectal cancer in users of GLP-1s versus aspirin
Analyzed data on drug usage and cancer development
Individuals on GLP-1s had a 36% lower risk of developing colorectal cancer compared to aspirin users
The absolute benefit was small on an individual level, but significant for the larger population

Abstract

In a large retrospective study, those taking a glucagon-like peptide 1 (GLP-1) receptor agonist drug were 36% less likely to develop colorectal cancer than those taking aspirin. Although the benefit seen for any one person was small, thousands could potentially see a benefit given the large number of people taking GLP-1s.d

AI से पूछें

Bookmark

View Full Paper

Cite This Study

A Wed, study studied this question.

synapsesocial.com/papers/696c774feb60fb80d1395998 https://doi.org/https://doi.org/10.1158/2159-8290.cd-nw2026-0002

AI से पूछें

Bookmark

View Full Paper